For UK pharmaceutical and life sciences leaders
Your referral network has stalled and traditional outreach is no longer opening doors
HCPs are harder to reach, their schedules are tighter, and your competitors are in the same waiting room. Without a dynamic engagement strategy, network growth does not recover on its own.
Two minutes. Solva follows up with specific referral network options.
- Stagnant or declining prescription rates for new products
- Low attendance at educational events or webinars
- Limited uptake of new clinical guidelines or treatment protocols
- Difficulty in recruiting HCPs for clinical trials or advisory boards
- Inefficient allocation of sales and marketing resources
- Increased workload for medical science liaisons (MSLs) to compensate for sales team access issues
- Underperformance of product launches, leading to significant revenue shortfalls
- Reduced return on investment (ROI) for marketing and sales efforts
- Delayed adoption of innovative treatments by HCPs, potentially impacting patient outcomes
- Suboptimal patient access to new and effective medications
- Perception of the company as outdated or out of touch with modern HCP engagement
- Difficulty in attracting top talent due to a reputation for ineffective market access
- The struggle to build and maintain effective HCP referral networks stems from several structural, behavioural, and systemic issues.
- HCPs face increasing time pressures and administrative burdens, limiting their availability for traditional sales representative visits.
- The shift towards digital engagement channels, while offering new avenues, also creates a fragmented landscape where pharma companies must compete for attention.
- Furthermore, a saturated market with numerous pharmaceutical companies vying for HCP mindshare makes it challenging to differentiate and establish sustained, valuable relationships.
In the UK, HCP access for biopharmas sits at 25% (Pharmaphorum, 2024)
How to fix it
Develop an omnichannel engagement strategy that combines digital platforms with targeted in-person interactions, tailored to individual HCP preferences. Leverage data analytics to identify key referral patterns and optimize resource allocation for network development.
Frequently asked questions
Why does this problem persist?
The evolving preferences of HCPs for digital engagement, coupled with time constraints and a saturated market, make traditional outreach methods less effective. Pharma companies often lack dynamic strategies to adapt to these changes and build sustained, valuable relationships.
What is the cost of leaving it unaddressed?
No verified UK data available
This is exactly what I do with UK private practices. Answer the few questions above and I'll come back personally with where to start. Paul.